Avillion   Report issue

For profit Phase 2 Phase 3
Founded: London United Kingdom (2012)

Organization Overview

First Clinical Trial
2014
NCT02130557
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Avillion LLP | Bond Avillion 2 Development LP

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Asthma (Phase 3)

Asthma, Exercise-Induced (Phase 3)

Bronchial Spasm (Phase 3)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Chronic-Phase (Phase 3)

Psoriasis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 6